title: Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.
abstract: For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies.
authors.affiliation: Hong Kong University of Science and Technology, Division of Biology Life Science, Hong Kong.
authors.forename: Karl
authors.initials: K
authors.lastname: Herrup
authors.forename: Maria C
authors.initials: MC
authors.lastname: Carrillo
authors.forename: Dale
authors.initials: D
authors.lastname: Schenk
authors.forename: Angela
authors.initials: A
authors.lastname: Cacace
authors.forename: Susan
authors.initials: S
authors.lastname: Desanti
authors.forename: Robert
authors.initials: R
authors.lastname: Fremeau
authors.forename: Ratan
authors.initials: R
authors.lastname: Bhat
authors.forename: Marcie
authors.initials: M
authors.lastname: Glicksman
authors.forename: Patrick
authors.initials: P
authors.lastname: May
authors.forename: Russell
authors.initials: R
authors.lastname: Swerdlow
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Van Eldik
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Bain
authors.forename: Samantha
authors.initials: S
authors.lastname: Budd
mesh_terms: D000375:Aging; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001343:Autophagy / Q000187:drug effects; D015415:Biomarkers; D001921:Brain / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D003299:Cooperative Behavior; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007249:Inflammation; D007333:Insulin Resistance; D008247:Lysosomes / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D008928:Mitochondria / Q000187:drug effects / Q000473:pathology; D008959:Models, Neurological; D058990:Molecular Targeted Therapy; D059906:Neuroimaging; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055818:Public-Private Sector Partnerships; D040841:Resource Allocation; D016875:tau Proteins / Q000187:drug effects / Q000502:physiology
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; C054369:MAPT protein, human; D018697:Nootropic Agents; D016875:tau Proteins